CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
QIMC Reports Multi-Component Hydrocarbon and Helium Soil-Gas Anomalies in the New-Salem Area, Cumberland Basin Project, Nova Scotia
